Upcoming Conference
Tampa, May 18, 2023

5 Things Oregon: Blue Button 2.0, Topical Agenda, Drug price transparency

| Sep 20, 2019 | Oregon

We are about 8 weeks out from our 2019 Oregon State of Reform Health Policy Conference and registration is already well ahead of previous years. There's a reasonable chance we will actually sell out this year, given the space allowances at the hotel. So, if you know you want to be with...[ Read More ]

Jennifer Kent dismissive of Medicaid drug bulk purchasing agreements with OR and WA

Emily Boerger | May 21, 2019 | California, Oregon, Washington

States along the West Coast are exploring the option of establishing bulk purchasing agreements as a means to drive down prescription drug costs. But, based off recent comments made by Jennifer Kent, Director of California’s Department of Health Care Services, it seems unlikely that California will team up with Oregon...[ Read More ]

5 Things Oregon: Drug pricing transparency, gubernatorial candidates, Topical Agenda

| Aug 23, 2018 | Oregon

We first launched our Oregon State of Reform Health Policy Conference in 2012.  Now, we cover six states, and soon to be eight. So, thank you.  Thanks for reading, thanks for attending, and thanks for your engagement. Your support has allowed us to grow over the years to be a...[ Read More ]

Prescription drug pricing task force meets to discuss cost factor transparency

Emily Boerger | Aug 22, 2018 | Oregon

The Joint Interim Task Force on Fair Pricing of Prescription Drugs held an informational meeting on Tuesday to explore policy strategies and legislative proposals to improve pharmaceutical pricing transparency in Oregon. The 18-member task force was established by HB 4005 during the 2018 legislative session and is charged with developing...[ Read More ]

Prescription drug pricing bill heads to Gov. Brown's desk

Emily Boerger | Mar 2, 2018 | Oregon

On Friday, the Senate passed a bill to create a statewide prescription drug pricing transparency program by a 25-4 vote. The bill would require prescription drug manufacturers to report information like production, marketing, and research costs of certain drugs to the Department of Business and Commerce (DCBS). They would also...[ Read More ]